Jump to navigation
In a perspective piece in the New England Journal of Medicine, CP3 Director Walid Gellad and HPI Director Everette James describe the controversy surrounding the 340B Drug Pricing Program.Read more.
In a recent article in JAMA, researchers compared prescription opioid use and medication-assisted treatment rates before and after an overdose.
In a recent perspective piece in NEJM, Dr. Gellad discusses the accelerated approval process in the era of expensive drugs. Read more.
In a commentary in JAMA Internal Medicine, Dr. Walid Gellad discusses the opioid epidemic within the Nation's Veteran population.
Each year the United States experiences a shortage of over 100 drugs. In an editorial in JAMA, Drs. Donohue and Angus explore the reasons.
Expanding veterans' access to providers outside of the VA may increase the risk for unsafe prescribing practices, particularly in persons with dementia. Read more.